Company:  GALENA BIOPHARMA, INC. (GALE)
Form Type:  8-K
Filing Date:  11/18/2011 
CIK:  0001390478 
Address:  4640 SW MACADAM AVENUE
SUITE 270
 
City, State, Zip:  PORTLAND, Oregon 97239 
Telephone:  855 855 GALE 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.35  
Change: 
-0.03 (-2.17%)  
Trade Time: 
Mar 27  
Market Cap: 
$207.67M

Description of Business
Galena Biopharma, Inc. ("we," "us," "our," "Galena" or the "company") is a biopharmaceutical company focused on developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax(TM) (nelipepimut-S) currently in an international, Phase 3 clinical trial. The company's commercial drugs include Abstral® (fentanyl) Sublingual Tablets and Zuplenz® (ondansetron) Oral Soluble Film. Collectively, Our clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects.
Register for a Free Trial and access this filing in:     
  FORM 8-K
    SECTION 3 SECURITIES AND TRADING MARKETS
      Item 3.01 Notice of Delisting or Failure to Satisfy a ...
    SIGNATURES